Skip to main content
. 2022 Jan 5;12:801493. doi: 10.3389/fphar.2021.801493

FIGURE 5.

FIGURE 5

Targeting TIGIT promoted the antitumor capability of T cells. (A) Administration of α-TIGIT does not affect the ratios of CD4+ and CD8+ T-cells in bladder cancer tissues. Dot plots represent the frequencies of CD4+ and CD8+ T cells in murine bladder cancer tissues from three independent experiments (n = 6) (left panel). The ratios of CD4+ and CD8+ T cells are shown as the mean (right panel). (B) Administration of α-TIGIT upregulates the secretion of IFN-γ in T cells. Numbers in histograms show the representative ratios of IFN-γ+ T cells from three independent experiments (n = 6) (left panel). The ratios of IFN-γ+ cells are shown as the mean ± SD. **p < 0.01; one-way ANOVA (right panel). (C) Administration of α-TIGIT suppresses the expression of TIGIT in Treg cells. Dot plots represent the ratios of TIGIT + CD25 + subsets in CD4+ T cells from three independent experiments (n = 6) (left panel). The ratios of TIGIT + CD25 + cells are shown as the mean ± SD. *p < 0.05; t-test (right panel). (D) Administration of α-TIGIT suppresses the generation of Treg cells in mice with bladder cancer. Dot plots represent the ratios of CD25 + FOXP3+ subsets in CD4+ T cells from three independent experiments (n = 6) (left panel). The ratios of CD25 + FOXP3+ cells are shown as the mean ± SD. *p < 0.05; t-test (right panel).